Small bowel metastases in non-small cell lung cancer

被引:52
作者
Stenbygaard, LE [1 ]
Sorensen, JB
机构
[1] Univ Copenhagen, Herlev Hosp, Dept Oncol, DK-2730 Herlev, Denmark
[2] Natl Univ Hosp, Rigshosp, Finsen Ctr, Dept Oncol, Copenhagen, Denmark
关键词
small bowel metastases; non-small cell lung cancer; autopsy;
D O I
10.1016/S0169-5002(99)00075-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A case report of stage I adenocarcinoma of the lung in a 43-year-old female with recurrence in the small bowel and liver 11 months after pneumonectomy is presented. In addition, a cohort of 733 patients with non-small cell lung cancer (NSCLC) in all pretreatment stages (stages I-IV) with a total of 218 autopsies are evaluated, and the literature on the topic is reviewed, in order to define the frequency of metastases from NSCLC to the small bowel. There were 10 cases with and 208 cases without small bowel involvement among 218 consecutive autopsies (autopsy rate, 30%). The frequency of small bowel involvement was 4.6% (95% confidence interval, 2.2-8.3%), and all were in patients with adenocarcinoma of the lung. Ail patients with small bowel involvement at autopsy had also other concurrent metastatic sites as well and the following were the most frequent: adrenals (90% of cases), mediastinal lymph nodes (80%), liver (70%), pleura (60%), contralateral lung (60%), bones (60%), and brain (50%). Significantly more metastatic sites were observed in patients with than without small bowel involvement, both totally (P = 0.0001) and with respect to number of extrathoracic (P = 0.0001) and intrathoracic (P = 0.01) metastatic sites. In conclusion, small bowel involvement in NSCLC is relatively infrequent. As a unique finding, over-representation of patients with poorly differentiated tumors (P = 0.03) and patients having solid carcinoma with mucus formation after histologic subtyping (P = 0.04) among cases with small bower involvement was observed. This indicates, that small bowel metastases is an epiphenomonen of NSCLC tumors with certain biological characteristics, although as yet undiscovered, which leads to a high metastatic potential. If such biological characteristics could be identified, they may be used in the selection of treatment options for individual patients, e.g. indicating a need for adjuvant or neoadjuvant chemotherapy in addition to surgery in resectable or marginally resectable NCSLC patients. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:95 / 101
页数:7
相关论文
共 23 条
[1]   SINGLE-AGENT ACTIVITY OF WEEKLY GEMCITABINE IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A PHASE-II STUDY [J].
ANDERSON, H ;
LUND, B ;
BACH, F ;
THATCHER, N ;
WALLING, J ;
HANSEN, HH .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (09) :1821-1826
[2]  
[Anonymous], 1979, HDB REP RES CANC TRE
[3]   PHASE-II TRIAL OF TCNU AND VINDESINE IN PATIENTS WITH ADENOCARCINOMA OF THE LUNG [J].
BACH, F ;
VIBEPETERSEN, J ;
SORENSEN, JB ;
DOMBERNOWSKY, P ;
HANSEN, HH .
EUROPEAN JOURNAL OF CANCER, 1990, 26 (04) :545-545
[4]  
LEE PN, 1994, APMIS, V102, P1
[5]   SMALL BOWEL PERFORATION SECONDARY TO METASTATIC LUNG-CARCINOMA [J].
LEIDICH, RB ;
RUDOLF, LE .
ANNALS OF SURGERY, 1981, 193 (01) :67-69
[6]   PHASE-II STUDY OF GEMCITABINE (2',2'-DIFLUORODEOXYCYTIDINE) GIVEN AS A TWICE WEEKLY SCHEDULE TO PREVIOUSLY UNTREATED PATIENTS WITH NONSMALL CELL LUNG-CANCER [J].
LUND, B ;
RYBERG, M ;
PETERSEN, PM ;
ANDERSON, H ;
THATCHER, N ;
DOMBERNOWSKY, P .
ANNALS OF ONCOLOGY, 1994, 5 (09) :852-853
[7]  
*LUNG CANC STUD GR, 1984, J CLIN ONCOL, V12, P1352
[8]  
MCNEILL PM, 1987, CANCER, V59, P1486, DOI 10.1002/1097-0142(19870415)59:8<1486::AID-CNCR2820590815>3.0.CO
[9]  
2-W
[10]  
MOUNTAIN CF, 1986, CHEST, V89, pS225, DOI 10.1378/chest.89.4.225S